RxDoctor Payments DataLook up a doctor →

Stephen Jones, MD

Family Medicine · Shelby, NCNPI 1730130881

Payments from drug & device makers

$4,545,125in general payments, 2019–2025

Across 523 payments — averaging $8690.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$951K
  • Genentech, Inc.$619K
  • Novartis$479K
  • Sanofi US Services Inc.$415K
  • Amgen$296K
  • GSK$284K
  • plus $1.5M from 28 others
$28,328in research payments, 2019–2025

Across 17 payments — averaging $1666.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$21K
  • Eli Lilly$6K
  • GSK$2K

What the payments were for

  • Travel & lodging$57625%
  • Food & beverage$1,70175%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,545,125 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$65,893
Medicare patients
337
Services billed
964

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$11,176
AbrysvoRsv Vacc, Pref A And Pref B/Pf35$11,142
ShingrixVaricella-Zoster Ge/As01b/Pf26$5,762
Albuterol Sulfate HfaAlbuterol Sulfate26$978
Levothyroxine Sodium28$394
Gabapentin24$371
Omeprazole27$257
Diclofenac Sodium19$244
Atorvastatin Calcium26$237
Rosuvastatin Calcium15$133
Fluconazole11$121
Metformin Hcl16$105
Losartan Potassium17$101
Amlodipine Besylate19$84
Prednisone11$79

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Shingrix$284,153$16,93840 claims
PfizerAbrysvo$279,446$11,14235 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Shelby

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →